Back to results
US 10,309,974 B2Granted
Citrullinated proteins: a post-translated modification of myocardial proteins as marker of physiological and pathological disease
AssigneeCedars-Sinai Medical Center
InventorsJustyna P. Fert-Bober, Jennifer E. Van Eyk
Life of this patent
Estimating the term…
Abstract
Disclosed herein are methods for diagnosing cardiovascular disease. The methods comprise detection of citrullinated proteins and/or citrullinated peptides. Also disclosed herein are methods, compositions, and kits for diagnosing and/or treating cardiovascular disease.
Claims20
A method for diagnosing and treating cardiovascular disease in a subject, comprising:
- obtaining a sample from the subject, wherein the sample is selected from the group consisting of heart tissue, blood, plasma, and serum;
- and wherein the subject is human;
- detecting an amount of one or more citrullinated proteins in the sample from the subject;
- comparing the amount of the citrullinated proteins in the sample from the subject to an amount of one or more citrullinated proteins from a reference sample, wherein a change in the amount of the citrullinated proteins in the sample from the subject relative to the amount of the citrullinated proteins from the reference sample is a diagnosis of cardiovascular disease in the subject,
- wherein the cardiovascular disease is selected from the group consisting of heart failure, ischemic heart disease (ISHD), and idiopathic dilated cardiomyopathy (IDCM);
- wherein the citrullinated proteins are selected from the group consisting of myosin heavy chain, myosin binding protein C, tropomyosin α1, tropomyosin 3, actin, lipoprotein lipase, sulfhydryl oxidase 2, putative zinc finger protein 818, disintegrin and metalloproteinase domain-containing protein 10, titin, Zinc finger ZZ-type and EF-hand domain-containing protein 1, serpin, and tRNA-dihydrouridine synthase;
- and wherein the citrullinated proteins comprise an amino acid sequence selected from the group consisting of SEQ ID NO:19, SEQ ID NO:20, SEQ ID NO:21, SEQ ID NO:22, SEQ ID NO:23, SEQ ID NO:24, SEQ ID NO:25, SEQ ID NO:26, SEQ ID NO:27, SEQ ID NO:28, SEQ ID NO:29, SEQ ID NO:30, SEQ ID NO:31, SEQ ID NO:32, SEQ ID NO:33, and SEQ ID NO:34;
- and
- administering a treatment to the subject based on the diagnosis, wherein the treatment comprises a therapeutically effective amount of one or more PAD inhibitors.
6 more elements
A method for treating cardiovascular disease in a subject in whom a change in an amount of one or more citrullinated proteins has been detected relative to an amount of one or more citrullinated proteins in a reference sample, comprising:
- providing a subject diagnosed with cardiovascular disease in whom a change in an amount of one or more citrullinated proteins has been detected relative to an amount of one or more citrullinated proteins in a reference sample, wherein the subject is human;
- wherein the cardiovascular disease is selected from the group consisting of heart failure, ischemic heart disease (ISHD), and idiopathic dilated cardiomyopathy (IDCM);
- wherein the citrullinated proteins are selected from the group consisting of myosin heavy chain, myosin binding protein C, tropomyosin α1, tropomyosin 3, actin, lipoprotein lipase, sulfhydryl oxidase 2, putative zinc finger protein 818, disintegrin and metalloproteinase domain-containing protein 10, titin, Zinc finger ZZ-type and EF-hand domain-containing protein 1, serpin, and tRNA-dihydrouridine synthase;
- and wherein the citrullinated proteins comprise an amino acid sequence selected from the group consisting of SEQ ID NO:
- 19, SEQ ID NO:20, SEQ ID NO:21, SEQ ID NO:22, SEQ ID NO:23, SEQ ID NO:24, SEQ ID NO:25, SEQ ID NO:26, SEQ ID NO:27, SEQ ID NO:28, SEQ ID NO:29, SEQ ID NO:30, SEQ ID NO:31, SEQ ID NO:32, SEQ ID NO:33, and SEQ ID NO:34;
- and
- administering a treatment to the subject, wherein the treatment comprises a therapeutically effective amount of one or more PAD inhibitors.
4 more elements
Dependencies are inferred from the claim text.